omniture
logo
Search
ABL BIO INC
Media Room

Latest News

rss

ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors

- MSD will supply KEYTRUDA to be evaluated in combination with ABL Bio's ABL103 in a Phase1b/2 clin...

2024-10-04 12:40 2414

ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

* ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecif...

2022-01-12 07:59 2757
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease

ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody

* South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and prelimi...

2021-08-04 21:30 1601

ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody

* ABL503/TJ-L14B demonstrates stronger anti-tumor efficacy than anti-PD-L1 or anti-4-1BB monother...

2021-07-09 21:00 2934